BSEBeryl Drugs LtdMediumPositive
Announced Fri, 13 Mar · 15:46 IST

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi

Promoter Stake BuyCreeping Acquisition Near ThresholdOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹20.20
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.7-1.0+3.9+5.9+1.5+0.5+28.7+21.4-0.5+16.3
Up moveDown movePending
AI summary

Mr. Sudhir Sethi, the main promoter of Beryl Drugs Limited, has acquired 15,000 equity shares of the company through an open market transaction on 12 March 2026. This represents 0.29% of the company's total share capital, raising his holding from 4,55,143 shares (8.98%) to 4,70,143 shares (9.27%). The disclosure was filed under Regulation 29(2) of the SEBI Takeover Regulations, 2011. The total equity share capital of the company remains unchanged at 50,71,700 shares.

Likely market impact

This is a small but positive signal — the promoter is increasing his personal stake in the company via open market purchase, indicating insider confidence. With holding now at 9.27%, the promoter is approaching the 10% mark, after which additional acquisition rules under SEBI takeover regulations would apply.